Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
19/01/2023 13:48
Jan 19 (Reuters) - BioCorRx Inc BICX.PK :
* BIOCORRX ANNOUNCES COMPLETION OF TREATMENT PHASE OF STUDY
SUBJECTS AND PRELIMINARY SAFETY DATA FROM PHASE I CLINICAL TRIAL
OF BICX104, AN IMPLANTABLE NALTREXONE PELLET FOR THE TREATMENT
OF OPIOID USE DISORDER
Source text for Eikon: ID:nGNXTRLVk
Further company coverage: BICX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocorrx
See all newsBrief: BioCorRx Submits Fast Track Application To FDA For Bicx104, An Implantable Biodegradable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: Biocorrx Announces Completion Of Treatment Phase Of Study Subjects And Preliminary Safety Data From Phase I Clinical Trial Of Bicx104
Brief: BioCorRx Partners With Government Plus To Expand Its Beat Addiction Recovery Program In The United States
Brief: Biocorrx Completes Final Subject Enrollment In Phase I Clinical Trial Of Bicx104, An Implantable Naltrexone Pellet For The Treatment Of Opioid Use Disorder
Brief: BioCorRx Begins Recruitment for Clinical Trial of BICX104